This specific peptide matrix is strictly for laboratory research and is commonly employed in the following investigational areas:

Synergistic Somatotropic Axis Modulation

The blend is utilized as a chemical probe to study the complex biophysics of pituitary receptor activation. Researchers use it to quantify the synergistic release of GH when the GHRH receptor and the ghrelin receptor are activated simultaneously, effectively bypassing somatostatin-mediated negative feedback in isolated neuroendocrine models.

Lipid Metabolism & Adipocyte Bioenergetics

Tesamorelin and GHRPs are heavily researched in metabolic models examining lipolysis and visceral adiposity. Assays focus on how amplified, pulsatile GH secretion alters lipid droplet mobilization, hepatic fat oxidation, and the preservation of lean body mass under metabolic stress.

Satellite Cell Activation and Tissue Hypertrophy

The inclusion of MGF directs research toward localized tissue repair. In vitro studies involving primary myoblasts utilize this blend to observe the proliferation of muscle satellite cells, mapping the molecular cascade that precedes cellular fusion and hypertrophic adaptation following mechanical or chemically induced damage.

Pathway / Mechanistic Context

The primary mechanism of action for this blend involves the integration of three distinct cellular signaling pathways:

• GHRHR Activation (Tesamorelin): Binds to GHRHR, activating adenylate cyclase, which increases intracellular cAMP and stimulates GH synthesis and release.
• GHSR-1a Activation (GHRP-2 & Ipamorelin): Binds to the ghrelin receptor, activating the phospholipase C (PLC) pathway. This increases inositol triphosphate (IP3) and diacylglycerol (DAG), leading to a rapid influx of intracellular calcium ions (Ca2+) and immediate GH vesicle exocytosis.
• Mechanosensitive Signaling (MGF): MGF initiates the extracellular signal-regulated kinase (ERK1/2) pathway independent of the mature IGF-1 receptor, rapidly stimulating the proliferation of mono-nucleated myoblasts before they terminally differentiate.

Preclinical Research Summary

Published preclinical literature documents investigations of these constituent peptides across multiple experimental models:

• Neuroendocrine Synergy: Studies demonstrate that co-administration of GHRH analogues and GHRPs elicits a GH pulse significantly greater than the sum of their individual effects, due to complementary intracellular signaling cascades and the inhibition of endogenous somatostatin.
• Cellular Regeneration: In vitro data suggests that MGF expression is a critical initial step in the muscle repair process, significantly upregulating satellite cell division in mechanically overloaded tissue models.
• Metabolic Homeostasis: Research indicates that the specific stimulation of the somatotropic axis via Tesamorelin alters cellular energy homeostasis, particularly promoting the oxidation of visceral adipose tissue while sparing glucose utilization in specific in vivo models.

Form & Analytical Testing

This material is produced via robust chemical synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and constituent identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Storage & Handling

Stable at room temperature for up to 90 days. For long-term storage, keep at -20C (-4F) or colder. Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4C (39F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 139(5), 552-561. https://doi.org/10.1530/eje.0.1390552
• Phung, L. T., Inoue, H., Koba, S., et al. (2000). Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) and GHRH on growth hormone secretion. Endocrine journal, 47(5), 589-595.https://pubmed.ncbi.nlm.nih.gov/11164330/
• Falutz, J., Allman, E. G., Blood, J., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
• Goldspink, G. (2005). Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda, Md.), 20, 232–238. https://doi.org/10.1152/physiol.00004.2005
• Penalva, M. C., Carballo, M., Pombo, M., et al. (2008). Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-2-induced GH secretion in man. The Journal of clinical endocrinology and metabolism, 76(1), 168-171. https://doi.org/10.1210/jcem.76.1.8421081

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.